Implementation of routine access to herpes simplex virus type 2 antibody testing in a public health sexually transmitted disease clinic

Sexually Transmitted Diseases

Volumn 36, Issue 11, 2009, Pages 724-728

  Fife, Kenneth H ^a,b,c   Van Der Pol, Barbara ^a,c   Roth, Alexis M ^a   Brand, Juanita ^c   Arno, Janet N ^a,c   Madlem, Jyl ^c   Juliar, Beth E ^a   Katz, Barry P ^a   Williams, James A ^a   Zimet, Gregory D ^b   Fortenberry, J Dennis ^b  

^a Departments of Medicine   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Marion County Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VIRUS ANTIBODY;

ADULT; AFRICAN AMERICAN; AGE; ANTIBODY DETECTION; ARTICLE; EUROPEAN AMERICAN; FEMALE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HISPANIC; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; SEXUAL BEHAVIOR; TREATMENT REFUSAL;

ACYCLOVIR; ADULT; AMBULATORY CARE FACILITIES; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEALTH PLAN IMPLEMENTATION; HEALTH SERVICES ACCESSIBILITY; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HUMANS; INDIANA; MALE; PATIENT COMPLIANCE; REAGENT KITS, DIAGNOSTIC; URBAN HEALTH;

EID: 70350752546     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181bc9a2f     Document Type: Article

References (12)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
3. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
4. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141-1149.
5. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: Implications for prevention of transmission. J Infect Dis 2008; 198:1098-1100.
6. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004; 31:665-669.
7. Fortenberry JD, Zimet GD, Brady R, et al. Return for results after herpes simplex virus type 2 screening. Sex Transm Dis 2004; 31:655-658. (Pubitemid 39426396)
8. Philip SS, Ahrens K, Shayevich C, et al. Evaluation of a new point-of-care serologic assay for herpes simplex virus type 2 infection. Clin Infect Dis 2008; 47:e79-e82.
9. Gunn RA, Gilchick RA, Joyce LK. Acceptance of herpes simplex virus type 2 screening among sexually transmitted disease clinic clients. Sex Transm Dis 2005; 32:328-329.
10. Leone P, Warren T, Hamed K, et al. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis 2007; 34:900-907.
11. Sperling RS, Fife KH, Warren TJ, et al. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sex Transm Dis 2008; 35:286-290.
12. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med